A. Cruceta

发表

The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection

G. M. Ortiz, D. Nixon, S. Bonhoeffer, 2001, AIDS.

Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1–Infected Patients Starting Efavirenz, Lopinavir–Ritonavir, or Atazanavir–Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial)

D. Podzamczer, B. Clotet, M. Plana, 2015, Journal of acquired immune deficiency syndromes.

Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial.

D. Podzamczer, M. Plana, A. Cruceta, 2010, AIDS research and human retroviruses.

Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir

A. Cruceta, M. Arnedo, M. Loncá, 2016, HIV medicine.

Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection.

Felipe García, M. Plana, A. Cruceta, 2005, The Journal of infectious diseases.

Immunologic reconstitution after 1 year of highly active antiretroviral therapy, with or without protease inhibitors.

M. Lejeune, Felipe García, M. Plana, 2002 .

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

Andrew Phillips, Esteban Martínez, Xavier Carné, 2001, AIDS.

Metabolic and Immunological Effects of Antiretroviral Agents in Healthy Individuals Receiving Post-Exposure Prophylaxis

Felipe García, G. Mestre, M. Plana, 2001, Antiviral therapy.

Efficacy and safety of fosfomycin plus imipenem versus vancomycin for complicated bacteraemia and endocarditis due to methicillin-resistant Staphylococcus aureus: a randomized clinical trial.

A. Cruceta, J. Miro, P. Muñoz, 2018, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[A study of 30 patients with bacteremia due to Campylobacter spp].

Ò. Miró, A. Cruceta, B. Coll-Vinent, 1997, Medicina clinica.

Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the Scan Study

J. Romeu, Felipe García, A. Cruceta, 2000, AIDS.

Genotypic and Phenotypic Resistance Patterns in Early-Stage HIV-1-Infected Patients Failing Initial Therapy with Stavudine, Didanosine and Nevirapine

Felipe García, G. Mestre, M. Plana, 2001, Antiviral therapy.

A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

D. Podzamczer, B. Clotet, J. Romeu, 1999, AIDS.

Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis

A. Cruceta, J. Miro, A. León, 2017, The Journal of antimicrobial chemotherapy.

Post-Exposure Prophylaxis for HIV Infection: A Clinical Trial Comparing Lopinavir/Ritonavir versus Atazanavir Each with Zidovudine/Lamivudine

B. Clotet, Felipe García, A. Cruceta, 2012, Antiviral therapy.

Thrice-Weekly Sulfadiazine-Pyrimethamine for Maintenance Therapy of Toxoplasmic Encephalitis in HIV-Infected Patients

D. Podzamczer, A. Cruceta, J. Miro, 2000, European Journal of Clinical Microbiology and Infectious Diseases.

Predictors of progression in chronically infected naive patients with plasma viraemia below 5000 copies/ml and CD4 T lymphocytes greater than 500 x 10(6)/I.

M. Plana, Á. Soriano, C. Vidal, 2001, AIDS.

Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection

Felipe García, M. Plana, Á. Soriano, 2000, AIDS.

Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.

M. Plana, C. Vidal, A. Cruceta, 1999, AIDS.

Residual low-level viral replication could explain discrepancies between viral load and CD4+ cell response in human immunodeficiency virus-infected patients receiving antiretroviral therapy.

M. Plana, C. Vidal, A. Cruceta, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Immunological function restoration with lopinavir/ritonavir versus efavirenz containing regimens in HIV-infected patients: a randomized clinical trial.

B. Clotet, E. Negredo, Felipe García, 2014, AIDS research and human retroviruses.

Predictors of Tonsillar Tissue HIV-1 Viral Burden at Baseline and after 1 Year of Antiretroviral Therapy

Felipe García, G. Mestre, M. Plana, 2002, Antiviral therapy.

The virological and immunological consequences of structured treatment interruptions in chronic HIV-1infection

J. Gatell, Á. Soriano, A. Cruceta, 2022 .

Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.

A. Cruceta, J. Mallolas, M. Laguno, 2016, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Long-term clinical follow-up, without antiretroviral therapy, of patients with chronic HIV-1 infection with good virological response to structured treatment interruption.

Felipe García, M. Plana, A. Cruceta, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Relevance of HIV-1-Specific CD4+ Helper T-Cell Responses During Structured Treatment Interruptions in Patients With CD4+ T-Cell Nadir Above 400/mm3

G. M. Ortiz, D. Nixon, C. Fagard, 2004, Journal of acquired immune deficiency syndromes.

Immunologic Reconstitution After 1 Year of Highly Active Antiretroviral Therapy, With or Without Protease Inhibitors

M. Lejeune, Felipe García, M. Plana, 2002, Journal of acquired immune deficiency syndromes.

[138 episodes of bacteremia or fungemia in patients with solid organ (renal or hepatic) transplantation].

A. Cruceta, M. Navasa, J. García-Valdecasas, 1994, Medicina clinica.

Transmission of hepatitis C virus by discarded-needle injury.

J. Gatell, A. Cruceta, P. Castro, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Influence of human immunodeficiency virus 1 infection and degree of immunosuppression in the clinical characteristics and outcome of infective endocarditis in intravenous drug users.

J. Gatell, A. Cruceta, J. Gatell, 1998, Archives of internal medicine.

Dose‐Finding Study of Once‐Daily Indinavir/Ritonavir Plus Zidovudine and Lamivudine in HIV‐Infected Patients

Á. Soriano, A. Cruceta, T. Pumarola, 2000, Journal of acquired immune deficiency syndromes.

Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.

B. Clotet, L. Ruiz, C. Vidal, 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Lack of evidence of a stable viral load set‐point in early stage asymptomatic patients with chronic HIV‐1 infection

B. Clotet, L. Ruiz, J. Romeu, 1998, AIDS.

Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.

B. Clotet, J. Romeu, A. Cruceta, 2000, Journal of acquired immune deficiency syndromes.